EU Merger Control and Harm to Innovation—A Long Walk to Freedom (from the Chains of Causation)

Abstract

In a string of recent merger decisions, culminating in the Dow/DuPont case, the European Commission has profoundly revisited its traditional analysis of innovation and, ultimately, introduced what some authors have labeled “a novel theory of harm in EU merger policy.” According to this theory, the Commission does not look at harm to innovation on a specific product market in which parties are developing similar pipeline products, but adopts a general assessment of harm to innovation, unrelated to a specific product market and without considering potential anticompetitive effects on this basis. The purpose of this article is to show that over the last few years, the European Commission has been progressively departing from a “traditional” theory of harm in its assessment of mergers affecting innovation. In particular, we argue that the novel theory of harm developed in Dow/DuPont, based on a generic prejudice to innovation, is the landing place of a long journey through which the Commission has progressively altered the analytical framework applicable to traditional cases affecting pipeline products/potential competitors. And while this stance may be inspired by a legitimate policy goal, it brings the Commission on a collision route with the principles of causation and symmetry governing European Union merger control analysis.